Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification.
Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Krug U, Wörmann B, Hiddemann W, Görlich D, Sauerland C, Steffen B, Einsele H, Neubauer A, Burchert A, Schäfer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hänel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Ruhnke L, Schetelig J, Middeke JM, Serve H, Baldus CD, Platzbecker U, Müller-Tidow C, Bornhäuser M, Herold T, Thiede C, Röllig C. Eckardt JN, et al. Among authors: hanel m. Leukemia. 2023 Nov;37(11):2282-2285. doi: 10.1038/s41375-023-02016-6. Epub 2023 Sep 7. Leukemia. 2023. PMID: 37679502 Free PMC article. No abstract available.
Extramedullary blast crisis of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation mimicking aggressive, translocation t(14;18)-positive B-cell lymphoma.
Kroschinsky F, Friedrich K, Hanel M, Mohr B, Langer T, Meinhardt M, Thiede C, Bornhauser M, Baretton G, Ehninger G. Kroschinsky F, et al. Among authors: hanel m. Ann Hematol. 2003 Jan;82(1):47-52. doi: 10.1007/s00277-002-0569-x. Epub 2002 Nov 29. Ann Hematol. 2003. PMID: 12574966
Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.
Platzbecker U, Haase M, Herbst R, Hänel A, Voigtmann K, Thiede CH, Mohr B, Schleyer E, Leopold T, Orth M, Hänel M, Ehninger G, Bornhäuser M. Platzbecker U, et al. Among authors: hanel m, hanel a. Br J Haematol. 2005 Mar;128(5):625-30. doi: 10.1111/j.1365-2141.2005.05360.x. Br J Haematol. 2005. PMID: 15725083 Free article.
Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission.
Strodtbeck D, Bornhäuser M, Hänel M, Lerche L, Schaich M, Illmer T, Thiede C, Geissler G, Herbst R, Ehninger G, Platzbecker U. Strodtbeck D, et al. Among authors: hanel m. Bone Marrow Transplant. 2005 Dec;36(12):1083-8. doi: 10.1038/sj.bmt.1705176. Bone Marrow Transplant. 2005. PMID: 16247435
Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia.
Platzbecker U, Thiede C, Füssel M, Geissler G, Illmer T, Mohr B, Hänel M, Mahlberg R, Krümpelmann U, Weissinger F, Schaich M, Theuser C, Ehninger G, Bornhäuser M. Platzbecker U, et al. Among authors: hanel m. Leukemia. 2006 Apr;20(4):707-14. doi: 10.1038/sj.leu.2404143. Leukemia. 2006. PMID: 16482208 Clinical Trial.
Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.
Bornhäuser M, Illmer T, Oelschlaegel U, Schetelig J, Ordemann R, Schaich M, Hänel M, Schuler U, Thiede C, Kiani A, Platzbecker U, Ehninger G. Bornhäuser M, et al. Among authors: hanel m. Clin Cancer Res. 2008 Sep 1;14(17):5585-93. doi: 10.1158/1078-0432.CCR-08-0894. Clin Cancer Res. 2008. PMID: 18765552 Clinical Trial.
Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia.
Müller-Tidow C, Klein HU, Hascher A, Isken F, Tickenbrock L, Thoennissen N, Agrawal-Singh S, Tschanter P, Disselhoff C, Wang Y, Becker A, Thiede C, Ehninger G, zur Stadt U, Koschmieder S, Seidl M, Müller FU, Schmitz W, Schlenke P, McClelland M, Berdel WE, Dugas M, Serve H; Study Alliance Leukemia. Müller-Tidow C, et al. Blood. 2010 Nov 4;116(18):3564-71. doi: 10.1182/blood-2009-09-240978. Epub 2010 May 24. Blood. 2010. PMID: 20498303 Free PMC article.
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Göhring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hänel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saußele S, Hochhaus A; SAKK; German CML Study Group. Hanfstein B, et al. Among authors: hanel m. Leukemia. 2012 Sep;26(9):2096-102. doi: 10.1038/leu.2012.85. Epub 2012 Mar 26. Leukemia. 2012. PMID: 22446502 Clinical Trial.
187 results